Axsome Therapeutics, Inc.AXSMNASDAQ
Loading
Operating Expenses Over TimeExpanding
Percentile Rank100
3Y CAGR+50.1%
5Y CAGR+50.3%
Year-over-Year Change
Expenses from normal business operations (SG&A, R&D, etc.)
3Y CAGR
+50.1%/yr
vs +61.7%/yr prior
5Y CAGR
+50.3%/yr
Consistent
Acceleration
-11.6pp
Decelerating
Percentile
P100
Near historical high
vs 5Y Ago
7.7x
Strong expansion
Streak
8 yr
Consecutive growthExpanding
| Period | Value | YoY Change |
|---|---|---|
| 2025 | $760.25M | +20.1% |
| 2024 | $632.95M | +32.9% |
| 2023 | $476.36M | +112.1% |
| 2022 | $224.64M | +80.1% |
| 2021 | $124.71M | +25.8% |
| 2020 | $99.14M | +47.7% |
| 2019 | $67.11M | +104.3% |
| 2018 | $32.85M | +20.9% |
| 2017 | $27.16M | -1.4% |
| 2016 | $27.54M | - |